

Figure S2. (**Aa**) and (**Ab**) Western blots showing that pre-treatment with BAPTA-AM or CPA alone, and co-application of U73122 or GF109203X did not change expression levels of TRPC1 proteins. Relative mean band intensities against control values are shown underneath blots (n=3 freshly isolated tissue lysates). (**Ba**) Western blots showing that scrambled shRNA, and PLCβ1 shRNA1 and shRNA2 sequences had no effect on expression of TRPC1 proteins (n=3 primary cultured cell lysates). (**Bb**) and (**Bc**) Western blots showing that PLCβ1 shRNA1 and shRNA2 sequences do not alter Gαq and β-actin expression levels (n=3 primary cultured cell preparations). (**Ca**) Co-immunoprecipitation with anti-TRPC1 antibodies followed by Western blotting with anti-Gαq or anti-PLCβ1 antibodies show that pre-treatment of vessel segments with CPA induced interactions between TRPC1 and these molecules. (**Cb**) to (**Cd**) Pre-treatment of vessels with BAPTA-AM or CPA did not alter expression levels of TRPC1, Gαq, and PLCβ1. (**Ce**) and (**Cf**) Pre-treatment with BAPTA-AM or CPA also had no effect on expression levels of PLCγ1 and co-immunoprecipitation with anti-PLCγ1 antibodies followed by Western blotting with anti-TRPC1 antibodies showed no interactions between these two molecules at rest or following pre-treatment with BAPTA-AM or CPA.